GSK enters agreement to acquire RAPT Therapeutics GSK plc (LSE NYSE: GSK) today announced that it has entered a definitive agreement to acquire RAPT Therapeutics (“RAPT”) (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE
Press Releases | RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s . . . About RAPT Therapeutics, Inc RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases The company leverages its proprietary discovery and development platform to advance both biologics and selective small molecules aimed at normalizing critical immune
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors About RAPT Therapeutics, Inc RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon . . . About RAPT Therapeutics, Inc RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology
Stock Information - RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
RAPT Therapeutics Announces $150 Million Private Placement RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant unmet needs in inflammatory diseases
Investor Relations | RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of . . . About RAPT Therapeutics, Inc RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases